Uncontrolled bleeding is a major cause of mortality. Lysine analogues are routinely used in the management of bleeding, but several studies indicate a risk of serious detrimental effects upon their administration. In this study, we report a bivalent conjugate “3218” of two RNA aptamers selected for binding to the serine protease tissue-type plasminogen activator (tPA), the principal initiator of fibrinolysis in mammals. The constituent monomeric aptamers, K32v2 and K18v2, were previously demonstrated to weakly inhibit fibrinolysis. We now show that K32v2 and K18v2 recognize distinct binding sites, presumably in the A- and B-chain of tPA, respectively. Both aptamers bind tPA with low nanomolar affinity and inhibit tPA-mediated activities in a way that is consistent with the proposed localization of their binding sites. The 3218 conjugate possesses the inhibitory activities of both K32v2 and K18v2 and additionally exhibits increased inhibitory efficiency relative to the monomeric aptamers. The 3218 conjugate proved an efficient inhibitor of fibrinolysis and may find application in the management of bleeding as a substitute for, or in combination with, currently used lysine analogues.
Get full access to this article
View all access options for this article.
References
1.
MurrayCJ and LopezAD. (1997). Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 349:1269–1276.
2.
SpahnDR, BouillonB, CernyV, CoatsTJ, DuranteauJ, Fernández-MondéjarE, FilipescuD, HuntBJ, KomadinaR, et al. (2013). Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care, 17:R76.
3.
HoffmanM, MonroeDM and RobertsHR. (1998). Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis, 9:s61–s65.
4.
FergussonDA, HébertPC, MazerCD, FremesS, MacAdamsC, MurkinJM, TeohK, DukePC, ArellanoR, et al. (2008). A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med, 358:2319–2331.
5.
DunnCJ and GoaKL. (1999). Tranexamic Acid: a review of its use in surgery and other indications. Drugs, 57:1005–1032.
6.
ShakurH, RobertsI, BautistaR, CaballeroJ, CoatsT, DewanY, El-SayedH, GogichaishviliT, GuptaS, et al. (2010). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet, 376:23–32.
7.
MartinK, WiesnerG, BreuerT, LangeR and TassaniP. (2008). The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg, 107:1783–1790.
8.
MurkinJM, FalterF, GrantonJ, YoungB, BurtC and ChuM. (2010). High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg, 110:350–353.
9.
KeylC, UhlR, BeyersdorfF, StampfS, LehaneC, WiesenackC and TrenkD. (2011). High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg, 39:e114–e121.
10.
KalavrouziotisD, VoisineP, MohammadiS, DionneS and DagenaisF. (2012). High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg, 93:148–154.
11.
Mindel JS. (1989). Problems in the use of tranexamic acid by ophthalmologists. Arch Ophthalmol, 107:486–487.
12.
RuddD, JaiserS, BradshawK and Archibald.N (2015). Going blind on dialysis: nyctalopia due to tranexamic acid. J Neurol Neurosurg Psychiatry, 86:e4.
13.
AnderssonL, ErikssonO, HedlundPO, KjellmanH and LindqvistB. (1978). Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urol Res, 6:83–88.
14.
de RossiSS and GlickM. (1996). Dental considerations for the patient with renal disease receiving hemodialysis. J Am Dent Assoc, 127:211–219.
15.
KooJR, LeeYK, KimYS, ChoWY, KimHK and WonNH. (1999). Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid). Nephrol Dial Transpl, 14:750–752.
16.
OdabasAR, CetinkayaR, SelcukY, KayaH, CoskunU, OdabaşAR, CetinkayaR, SelçukY, KayaH and CoşkunU. (2001). Tranexamic-acid-induced acute renal cortical necrosis in a patient with haemophilia A. Nephrol Dial Transpl, 16:189–190.
17.
ImbesiS, NettisE, MinciulloPL, Di LeoE, SaijaA, VaccaA and GangemiS. (2010). Hypersensitivity to tranexamic acid: a wide spectrum of adverse reactions. Pharm World Sci, 32:416–419.
18.
LevinEG, MarzecU, AndersonJ and HarkerLA. (1984). Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest, 74:1988–1995.
19.
SchrauwenY, de VriesREM, KooistraT and EmeisJJ. (1994). Acute release of tissue-type plasminogen activator (t-PA) from the endothelium; regulatory mechanisms and therapeutic target. Fibrinolysis, 8:8–12.
20.
WimanB and WallénP. (1977). The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thromb Res, 10:213–222.
21.
van ZonneveldAJ, VeermanH and PannekoekH. (1986). Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci U S A, 83:4670–4674.
22.
RånbyM. (1982). Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta, 704:461–469.
23.
HoylaertsM, LijnenHR and CollenD. (1981). Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta, 673:75–85.
BjerregaardN, AndreasenPA and DupontDM. (2016). Expected and unexpected features of protein-binding RNA aptamers. WILEY Interdiscip Rev RNA, 7:744–757.
26.
DupontDM, ThuesenCK, BøtkjærKA, BehrensMA, DamK, SørensenHP, PedersenJS, PlougM, JensenJK and Andreasen.PA (2015). Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites. PLoS One, 10:e0119207.
27.
ZukerM. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res, 31:3406–3415.
GongL, LiuM, ZengT, ShiX, YuanC, AndreasenPA and HuangM. (2015). Crystal structure of the michaelis complex between tissue-type plasminogen activator and plasminogen activators inhibitor-1. J Biol Chem, 290:25795–25804.
30.
BotkjaerKA, FoghS, BekesEC, ChenZ, BlouseGE, JensenJM, MortensenKK, HuangM, DeryuginaE, et al. (2011). Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies. Biochem J, 438:39–51.
31.
BennettWF, PaoniNF, KeytBA, BotsteinD, JonesAJS, PrestaL, WurmFM and ZollerMJ. (1991). High resolution analysis of functional determinants on human tissue-type plasminogen activator. J Biol Chem, 266:5191–5201.
32.
Bassel-DubyR, JiangNY, BittickT, MadisonE, McGookeyD, OrthK, ShohetR, SambrookJ and GethingMJ. (1992). Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor. J Biol Chem, 267:9668–9677.
33.
SkeldalS, LarsenJV, PedersenKE, PetersenHH, EgelundR, ChristensenA, JensenJK, GliemannJ and AndreasenPA. (2006). Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis. FEBS J, 273:5143–5159.
34.
DupontDM, BjerregaardN, VerpaalenB, AndreasenPA and JensenJK. (2016). Building a molecular trap for a serine protease from aptamer and peptide modules. Bioconjug Chem, 27:918–926.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
